证券代码： 300272 证券简称：开能健康 开能健康科技集团股份有限公司投资者关系活动记录表 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | --- | | 类别 | □ 媒体采访 √ 业绩说明会 | | | 路演活动 □ 新闻发布会 □ | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 5 月 17 日 (周三) 下午 13:00~15:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事长瞿建国 | | 员姓名 | 2、副董事长,总经理 QU RAYMOND MING（瞿建明） | | | 3、财务总监刘文军 | | | 4、董秘徐延茂 | | | 5、独立董事谢荣兴 投资者提出的问题及公司回复情况 | | | 1、公司 2023 | | | 公司就投资者在本次说明会中提出的问题进行了回复： 年研发投入比例大概是多少？研发人 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 372,040,366.05, representing a 10.79% increase compared to CNY 335,819,450.56 in the same period last year[5] - Net profit attributable to shareholders was CNY 16,605,727.28, up 4.28% from CNY 15,924,291.20 year-on-year[5] - The company reported a basic earnings per share of CNY 0.0296, which is a 5.34% increase from CNY 0.0281 in the same period last year[5] - Total operating revenue for Q1 2023 was CNY 372,040,366.05, an increase of 10.5% compared to CNY 335,819,450.56 in Q1 2022[24] - Net profit for Q1 2023 was CNY 17,525,658.71, a decrease of 11.3% from CNY 19,769,782.43 in Q1 2022[25] - The total comprehensive income for the first quarter of 2023 was CNY 16,760,127.96, compared to CNY 20,079,828.01 in the same period last year, reflecting a decrease of approximately 16.4%[26] Cash Flow - The net cash flow from operating activities reached CNY 53,035,355.56, a significant increase of 1,988.09% compared to a negative cash flow of CNY -2,808,939.15 in the previous year[5] - The net cash flow from financing activities was CNY 78,892,355.95, a dramatic increase of 3,835.14% compared to CNY 2,004,818.58 in the previous year[9] - The total cash inflow from operating activities was CNY 397,018,358.38, slightly down from CNY 405,228,257.23 in the previous year, reflecting a decrease of 2.9%[27] - The company generated CNY 388,070,676.86 in cash from sales of goods and services, an increase from CNY 381,649,254.79 in the same quarter last year, showing a growth of 1.1%[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,358,072,021.45, reflecting a 1.90% increase from CNY 2,314,014,391.36 at the end of the previous year[5] - Current liabilities rose to CNY 933,181,345.32 in Q1 2023, compared to CNY 897,329,240.01 in Q1 2022, indicating an increase of 4.0%[23] - The company reported a decrease in total liabilities to CNY 1,223,828,412.91 in Q1 2023 from CNY 1,196,530,910.78 in Q1 2022, a decline of 2.3%[23] - The total equity attributable to shareholders increased to CNY 1,106,206,777.37 in Q1 2023, up from CNY 1,090,276,172.70 in Q1 2022, representing a growth of 1.5%[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 23,343[11] - The largest shareholder, Qu Jianguo, holds 33.72% of the shares, totaling 194,638,209 shares[11] - The top ten shareholders collectively hold 146,539,043 restricted shares, with Qu Jianguo having 145,978,657 shares locked up[14] - The company has a total of 15,467,120 shares held in repurchase accounts among the top ten shareholders[12] - The total number of shares held by the top ten unrestricted shareholders is 48,659,552 shares for Qu Jianguo[11] - The total number of shares held by the top ten shareholders is significant, indicating concentrated ownership[11] Share Repurchase and Convertible Bonds - The company plans to repurchase shares using a maximum of 5,000,000 yuan, with a repurchase price not exceeding 7.4 yuan per share, potentially acquiring approximately 675,675.6 shares, or 1.17% of total equity[16] - The company has adjusted the maximum repurchase price from 7.5 yuan to 7.4 yuan per share following a cash dividend distribution of 0.1 yuan per share[16] - The company repurchased a total of 5,467,100 shares at an average price of 6.05 yuan per share, utilizing 31,367,162 yuan, which represents approximately 0.947% of the company's total shares[17] - As of March 31, 2023, the company held 15,467,120 shares in its repurchase account, accounting for about 2.68% of the total share capital[17] - The company plans to issue convertible bonds to unspecified investors, with an expected fundraising amount not exceeding 250 million yuan[18] - The convertible bonds will have a face value of 100 yuan each and a term of six years from the date of issuance[18] - The company’s board of directors approved the issuance of convertible bonds, which was subsequently ratified by the shareholders' meeting[18] Expenses - Financial expenses rose by 248.47% to CNY 11,570,325.35, mainly due to foreign exchange losses and increased interest expenses[8] - Research and development expenses for Q1 2023 were CNY 14,635,763.55, compared to CNY 13,260,879.81 in Q1 2022, marking an increase of 10.4%[25] - The company reported a decrease in tax expenses by 36.58% to CNY 3,039,107.74, attributed to a decline in profits[8] Inventory and Receivables - Accounts receivable decreased from 228,995,604.19 yuan at the beginning of the year to 205,737,316.04 yuan by the end of March 2023[21] - Inventory decreased from 322,242,963.51 yuan at the beginning of the year to 286,353,697.49 yuan by March 31, 2023[21]

Financial Performance - The company's operating revenue for 2022 was ¥1,660,642,447.43, representing a 9.87% increase compared to ¥1,511,487,428.56 in 2021[18]. - The net profit attributable to shareholders decreased by 11.57% to ¥92,730,943.47 from ¥104,859,883.20 in the previous year[18]. - The net profit after deducting non-recurring gains and losses increased by 16.30% to ¥73,666,732.03 from ¥63,339,903.42 in 2021[18]. - The net cash flow from operating activities was ¥155,435,268.00, down 16.78% from ¥186,767,653.57 in the previous year[18]. - Basic and diluted earnings per share were both ¥0.16, a decrease of 11.11% from ¥0.18 in 2021[18]. - Total assets at the end of 2022 were ¥2,314,014,391.36, an increase of 8.49% from ¥2,132,858,918.73 at the end of 2021[18]. - The net assets attributable to shareholders decreased by 9.33% to ¥1,090,276,172.70 from ¥1,202,418,915.04 in the previous year[18]. - The weighted average return on net assets was 7.63%, down from 8.90% in 2021[18]. Cash Flow and Investments - The net cash flow from investing activities improved significantly by 11,547.31%, resulting in a net outflow of ¥59,810,075.25, primarily due to equity investments[77]. - The net cash flow from financing activities increased by 132.07% to ¥30,983,047.00, driven by higher net borrowings and increased dividends[78]. - Cash and cash equivalents increased by 56.29% to ¥141,430,053.74, influenced by changes in operating and financing cash flows[78]. - The company's monetary funds rose to ¥413,099,191.78, accounting for 17.85% of total assets, up from 13.20% at the beginning of the year[81]. - Long-term equity investments increased significantly by ¥136,774,127.94, representing 5.91% of total assets, due to a ¥101 million investment in Yuaneng Bio[81]. Market and Product Development - The company has developed a comprehensive range of water treatment products, with over 1,700 specifications, and exports to more than 100 countries and regions[30]. - The penetration rate of water purifiers in China is approximately 18.3 units per 100 households, significantly lower than over 70% in developed countries, indicating substantial market potential[29]. - The company continues to focus on R&D in water treatment technologies, maintaining its position as a leader in the industry with multiple key technologies[27]. - The marketing model includes direct sales and distribution channels, targeting both domestic and international markets, with a focus on high-end consumers in first-tier cities[34]. - The company aims to expand its market presence by replicating successful sales models in other cities beyond Shanghai[34]. Research and Development - The company has a strong focus on R&D, continuously improving its product offerings to meet market demands[42]. - Research and development expenses rose by 22.40% to ¥66,815,186.24 in 2022, compared to ¥54,586,083.02 in 2021[73]. - The company increased its R&D personnel from 139 in 2021 to 169 in 2022, representing a growth of 21.58%[75]. - The proportion of R&D personnel rose from 9.22% in 2021 to 11.03% in 2022, an increase of 1.81%[75]. Corporate Governance and Social Responsibility - The company emphasizes the importance of social responsibility and stakeholder communication to maximize interests for shareholders, employees, and society[138]. - The company maintains independence from its controlling shareholders in terms of business, personnel, assets, and finance[139]. - The company strictly adheres to legal and regulatory requirements for information disclosure, ensuring transparency[138]. - The company has a complete and independent business operation capability[139]. Risks and Challenges - The company faces various risks including market risks, overseas operational risks, and financial risks from acquisitions, which may impact future performance[3]. - The company faces risks from intense market competition and is committed to leveraging its product, brand, and innovation advantages to maintain its competitive edge[127]. - The company faces risks of rising operating costs due to increasing labor costs and raw material prices, prompting efforts to enhance production automation and supply chain management[129]. - There is a risk of talent shortages that may hinder business development, leading the company to focus on attracting and stabilizing core teams through effective employee incentive systems[129]. Employee and Management - The total number of employees at the end of the reporting period was 1,532, with 856 in the parent company and 676 in major subsidiaries[159]. - The company has a total of 1,568 employees receiving compensation during the reporting period[159]. - The company has implemented a comprehensive salary management system, including monthly salary, hourly wage, annual salary, and contract wage systems[161][162]. - The company has focused on employee training, with over 300 employees completing online courses related to product innovation and digital transformation[164]. Environmental Initiatives - The company has established a comprehensive environmental management system and has not experienced any environmental pollution incidents[182]. - The company has invested over 1 million yuan in the renovation of a natural river, transforming it from a polluted state to a clean waterway, which has become a model for regional environmental governance[185]. - The company implements a full water reuse negative emission system, significantly reducing wastewater discharge through advanced technology and biological treatment[185].

证券代码：300272 证券简称：开能健康 公告编号：2023-022 开能健康科技集团股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 开能健康科技集团股份有限公司（以下简称"公司"）于2023年4月28日披露 了《2022年年度报告》。为方便广大投资者更深入全面地了解公司2022年度报告 及经营情况，公司将于2023年5月17日下午13:00-15:00举行2022年度网上业绩说 明会，本次说明会将采用网络远程的方式举行，投资者可登录全景网"投资者关 系互动平台"（http://rs.p5w.net）参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长瞿建国先生、总经理瞿亚明 先生、独立董事谢荣兴先生、财务总监刘文军先生及董事会秘书徐延茂先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 16 日 17：00 前访问 http://ir.p5w.net/zj/，或扫描下 ...

证券代码：300272 证券简称：开能环保 上海开能环保设备股份有限公司 投资者关系活动记录表 编号： | --- | --- | --- | |----------------|--------------------|------------------------------------------------------------| | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | ■ 现场参观调研 | | | | □ 其他 | | | 参与单位名称及 | 调研人员名单 | | | 人员姓名 | | 富根控股：王磊、冀东梅、邝庆华、谭丽珍、张璐、黄伟泉、杨 | | | | 涛、赖连书、林燕萍、蔡婷、王淑贞、邓雨雯、陈丽漳、林颖敏、 | | | | 陈小云；德邦证券：张伟、陈镇波、田魁；平安证券：邓炳 | | | | 东、丛涌、周其文；东莞证券：邹国辉、温宝琳、谢惠娟； | | | 中航证券： | 于曼、南坤、区文发；中原证券：吴剑雄；恒悦投 | | | | 资：张 ...

证券代码：300272 证券简称：开能环保 上海开能环保设备股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|------------------------------------------------------------------| | | | | | | 编号： | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | √ | 其他（深交所联合深圳证监局在公司举办"践行中国梦·走 | | | 近上市公司" 投资者开放日） | | | 参与单位名称及 | 1 申万宏源、东方证券等报名的 | 、通过国元证券、上海证券、湘财证券、光大证券、 70 名投资者； | | | | | | 人员姓名 | 2 3 、深交所相关领导。 | 、证券时报、深交所信息公司、第一财经等 6 人； | | 时间 | 2016 年 7 月 14 | 日上午 9 ...

证券代码：300272 证券简称：开能环保 上海开能环保设备股份有限公司 投资者关系活动记录表 编号： | --- | --- | --- | |----------------|-----------------------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | ■ 现场参观调研 | | | | □ 其他 | | | 参与单位名称及 | 调研人员名单 | | | 人员姓名 | | 南京证券倪翔、尚雅投资汪新文、国信证券杨辉、华创证券宋 | | | | 凯、浙商证券戴颖、中银国际吴炉飞、招商基金赵伟、原点资产 | | | | 彭瀚达、华创证券王逸萌、中银国际张威亚、华创证券王昊、兴 | | | | 证投资魏伟、中银国际杨志威、信达澳银基金杨珂 | | 时间 | 14:30-17:00 | | | 地点 | 上海浦东新区哈 ...

证券代码：300272 证券简称：开能环保 上海开能环保设备股份有限公司 投资者关系活动记录表 编号： | --- | --- | --- | |-----------------------|--------------------------|---------------------------------------------------------------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | | 中投证券 孙佳俊、海通资管 张雯、西南证券 龚梦泓、 | | 人员姓名 | 邹翠利、华宝信托 李华等 | 海通证券 李阳、海通证券 朱默辰、小牛投资 许超逸、国元证券 30 人 | | 时间 | 2016 年 12 月 20 | 日 13:30-16:00 | | 地点 | 上海市浦东新区川大路 | 518 号开能环保总部会议室 | | | | | | 上市公司接待人 ...

证券代码：300272 证券简称：开能健康 开能健康科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------------|--------------------------------------------|-----------------------------------------------------------------|-------| | | | | | | | 编号： | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | | 类别 | □ | 媒体采访 □业绩说明会 | | | | □ | 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | √ | 其他（深交所 "践行中国梦·走进开能健康" 投资者开放 | | | | 日） | | | | 参与单位名称及 | 1 | 、通过海通证券、国泰君安、广发证券、申万宏源、上海证 | | | 人员姓名 | 券等报名的 40 2 | 名投资者； 、深交所投教中心、投服中心、证券时报、全景网、第一财 | | | 时间 | 经广播、第一财经 ...